Leaving Wall Street

After spending more than a decade as a biotech analyst at Needham & Co., Mark Monane say he took the CMO's job at diagnostic company CardioDx Inc. because he was looking for an opportunity to work more closely with patients again. Monane holds an M.D. from New York University.

CardioDx markets the RNA-based Corus CAD test, which it says is the only clinically validated blood-based test for obstructive coronary artery disease (CAD). The company hopes its test, which lists at $1,195, will be used frontline for patients with stable chest pain...